INOVIO PHARMACEUTICALS, INC. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 82/100
What the filing says
INOVIO received FDA accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), a plasmid DNA immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP). The approval is based on RRP-001 trial data (n=32 patients): 7 of 26 efficacy-evaluable patients (27%) achieved complete response (no surgeries required in 12 months post-treatment) versus median 4.5 pre-treatment surgeries annually. VOCERYQ will launch Q1 2027 with availability to order/ship in ~60 days; INOVIO estimates 25,000+ RRP patients in U.S. market. Continued approval contingent on confirmatory study protocol due end-2026, finalized mid-2027.
Why this rating
First commercial product approval transforms INOVIO from pipeline biotech to revenue-generating company. $74.3M market cap company; rare disease with concentrated prescriber base (~400 laryngologists) and established manufacturing/field infrastructure. Material near-term catalyst and proof-of-platform validation, but small trial size (27% response rate, n=7) and accelerated approval contingency present execution risk.
Price action (we called it positive)
before filing · preread $1.99 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.